CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $39,368
- in 1 filing
Net +$960,625. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 3 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-10-21 | Kleiner Perkins Caufield & Byers XV, LLC 10% owner | Conversion | +55,314 | 77,621 | ||
| 2014-10-21 | Kleiner Perkins Caufield & Byers XV, LLC 10% owner | Conversion · Series A Preferred Stock | −1,244,871 | 0 | ||
| 2014-10-21 | Kleiner Perkins Caufield & Byers XV, LLC 10% owner | Conversion · Series B Preferred Stock | −607,234 | 0 | ||
| 2014-10-21 | Kleiner Perkins Caufield & Byers XV, LLC 10% owner | Conversion · Series A Preferred Stock | −37,179 | 0 | ||
| 2014-10-21 | Kleiner Perkins Caufield & Byers XV, LLC 10% owner | Conversion · Series B Preferred Stock | −18,136 | 0 | ||
| 2014-10-21 | Gallagher Carol Giltner Director | Conversion | +33,475 | 33,475 | ||
| 2014-10-21 | Gallagher Carol Giltner Director | Purchase | +18,181 | $11.00 | $200K | 51,656 |
| 2014-10-21 | Gallagher Carol Giltner Director | Grant or award · Restricted Stock Unit | +44,871 | 44,871 | ||
| 2014-10-21 | Gallagher Carol Giltner Director | Grant or award · Restricted Stock Unit | +24,776 | 24,776 | ||
| 2014-10-21 | Gallagher Carol Giltner Director | Grant or award · Restricted Stock Unit | +13,076 | 13,076 | ||
| 2014-10-21 | Gallagher Carol Giltner Director | Conversion · Series A Preferred Stock | −22,500 | 0 | ||
| 2014-10-21 | Gallagher Carol Giltner Director | Conversion · Series B Preferred Stock | −10,975 | 0 | ||
| 2014-10-21 | Fust Matthew K Director | Grant or award · Restricted Stock Unit | +25,640 | 25,640 | ||
| 2014-10-21 | Haqq Christopher Chief Medical Officer | Grant or award · Restricted Stock Unit | +13,266 | 13,266 | ||
| 2014-10-21 | MCGRATH JOHN Chief Financial Officer | Grant or award · Restricted Stock Unit | +44,871 | 44,871 | ||
| 2014-10-21 | MCGRATH JOHN Chief Financial Officer | Grant or award · Restricted Stock Unit | +123,158 | 123,158 | ||
| 2014-10-21 | Soffer Gad Chief Operating Officer | Grant or award · Restricted Stock Unit | +153,846 | 153,846 | ||
| 2014-10-21 | Soffer Gad Chief Operating Officer | Grant or award · Restricted Stock Unit | +66,332 | 66,332 | ||
| 2014-10-21 | Ciechanover Isaac E. Chief Executive Officer | Grant or award · Restricted Stock Unit | +94,523 | 94,523 | ||
| 2014-10-21 | Clark Mitchall G. Chief R & QA Officer | Grant or award · Restricted Stock Unit | +115,384 | 115,384 |
Page 69 of 71 · 1,403 trades